| Information regarding our geographic activities |
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
(In thousands) |
2013 |
|
2012 |
|
2013 |
|
2012 |
Product revenues: |
|
|
|
|
|
|
|
Pharmaceuticals |
$ |
18,618 |
|
|
$ |
9,917 |
|
|
$ |
34,145 |
|
|
$ |
18,556 |
|
Diagnostics |
— |
|
|
— |
|
|
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
18,618 |
|
|
$ |
9,917 |
|
|
$ |
34,145 |
|
|
$ |
18,556 |
|
Revenue from services and transfer of intellectual property: |
|
|
|
|
|
|
|
Pharmaceuticals |
$ |
1,300 |
|
|
$ |
— |
|
|
$ |
13,800 |
|
|
$ |
— |
|
Diagnostics |
3,823 |
|
|
243 |
|
|
7,132 |
|
|
330 |
|
Corporate |
80 |
|
|
51 |
|
|
120 |
|
|
102 |
|
|
$ |
5,203 |
|
|
$ |
294 |
|
|
$ |
21,052 |
|
|
$ |
432 |
|
Operating (loss) income: |
|
|
|
|
|
|
|
Pharmaceuticals |
$ |
(4,528 |
) |
|
$ |
(1,955 |
) |
|
$ |
3,955 |
|
|
$ |
(3,317 |
) |
Diagnostics |
(6,750 |
) |
|
(4,356 |
) |
|
(16,384 |
) |
|
(9,025 |
) |
Corporate |
(5,762 |
) |
|
(3,030 |
) |
|
(10,787 |
) |
|
(5,846 |
) |
Less: Operating loss attributable to noncontrolling interests |
(943 |
) |
|
— |
|
|
(1,540 |
) |
|
— |
|
|
$ |
(17,983 |
) |
|
$ |
(9,341 |
) |
|
$ |
(24,756 |
) |
|
$ |
(18,188 |
) |
Depreciation and amortization: |
|
|
|
|
|
|
|
Pharmaceuticals |
$ |
1,702 |
|
|
$ |
1,575 |
|
|
$ |
3,397 |
|
|
$ |
3,025 |
|
Diagnostics |
1,704 |
|
|
835 |
|
|
3,393 |
|
|
1,669 |
|
Corporate |
45 |
|
|
44 |
|
|
90 |
|
|
88 |
|
|
$ |
3,451 |
|
|
$ |
2,454 |
|
|
$ |
6,880 |
|
|
$ |
4,782 |
|
Revenues: |
|
|
|
|
|
|
|
United States |
$ |
5,203 |
|
|
$ |
294 |
|
|
$ |
21,052 |
|
|
$ |
432 |
|
Chile |
8,482 |
|
|
7,187 |
|
|
16,223 |
|
|
12,888 |
|
Spain |
5,153 |
|
|
— |
|
|
9,477 |
|
|
— |
|
Israel |
3,995 |
|
|
1,518 |
|
|
6,567 |
|
|
3,145 |
|
Mexico |
988 |
|
|
1,212 |
|
|
1,878 |
|
|
2,523 |
|
|
$ |
23,821 |
|
|
$ |
10,211 |
|
|
$ |
55,197 |
|
|
$ |
18,988 |
|
|
|
|
|
|
|
|
|
|
(In thousands) |
June 30,
2013 |
|
December 31,
2012 |
Assets: |
|
|
|
Pharmaceuticals |
$ |
336,266 |
|
|
$ |
142,299 |
|
Diagnostics |
114,095 |
|
|
112,422 |
|
Corporate |
190,719 |
|
|
35,109 |
|
|
$ |
641,080 |
|
|
$ |
289,830 |
|
Goodwill: |
|
|
|
Pharmaceuticals |
$ |
34,480 |
|
|
$ |
32,844 |
|
Diagnostics |
47,606 |
|
|
47,606 |
|
Corporate |
— |
|
|
— |
|
|
$ |
82,086 |
|
|
$ |
80,450 |
|
|